hotspot -WSS

hotspot

author：focus 2025-09-06 04:15:00 - browse：21

Christine Kao/STAT

The Food and Drug Administration’s approval on Friday of two gene therapies for sickle cell disease sets up what could be an intense competition between Bluebird Bio, maker of Lyfgenia, and the partnership of Vertex Pharmaceuticals and CRISPR Therapeutics, whose drug is Casgevy.

For the first time, physicians and patients will have a choice of potentially curative treatments for an inherited disease that affects nearly 100,000 Americans.

The Vertex/CRISPR team would seem to have the edge. As the first CRISPR-based therapy, Casgevy has the advantage of being powered by the latest and buzziest biological technology, though some physicians and patients may be more comfortable with the lentiviral vector technology behind Lyfgenia, which dates back to the 1990s — even with a “black box” warning of a risk of blood cancer added to its label.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Antibiotic resistance nearly killed me, so I'm raising awareness of it

leisure time

WSS

BD to buy Edwards patient monitoring unit for $4.2 billion

Biohaven protein

Biohaven protein

Adam's Biotech Scorecard: Do Sarepta's exon

Scientists successfully use ultrasound imaging to map brain activity

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

focus

hotspot

leisure time

Moonlake's readout produced a cash windfall. Risks remain

How CO2 helps viruses stay alive longer in the air

As demand for Covid shots wanes, Moderna seeks its next success

Adam's Biotech Scorecard: Do Sarepta's exon

Medicare details structure of new drug price negotiation program

Adam's Biotech Scorecard: Do Sarepta's exon

Affirmative action in medical school literally saved lives

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Sports medicine is finally prioritizing gender equality

Senators tussle over abortion against the backdrop of a presidential campaign

entertainment

'Little Tech' descents on D.C., wanting a say in how AI is regulated

Scientists successfully use ultrasound imaging to map brain activity

Prosthetic arm enables patients to feel the objects they grip

CMS got Medicare Advantage quality rating wrong, judge rules

'Little Tech' descents on D.C., wanting a say in how AI is regulated

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

hotspot

leisure time

entertainment

leisure time